| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
AJ2-30 targets SLC15A4. It inhibits SLC15A4-mediated MDP transport with an IC50 of 2.6 μM and suppresses IFN-α production with an IC50 of 1.8 μM. SLC15A4 is a transporter involved in innate immune signaling, and its inhibition modulates inflammatory responses.
|
|---|---|
| ln Vitro |
In vitro, AJ2-30 (5 μM, 24 h) inhibits TLR7, TLR7/8, and TLR9-induced IFN-α production in human plasmacytoid dendritic cells (pDCs). It also inhibits bacterial dipeptides MDP and TriDAP-mediated NOD1 and NOD2 signaling in primary human macrophages. AJ2-30 inhibits TLR9-mediated B cell activation.
|
| ln Vivo |
In vivo, AJ2-30 suppresses inflammatory cytokine production in lupus patient-derived PBMCs. It also inhibits endolysosomal TLR7-9-mediated mTOR activation. These findings support its potential for studying autoimmune and inflammatory diseases.
|
| Enzyme Assay |
SLC15A4 transport activity is measured using MDP uptake assays. AJ2-30 is incubated with SLC15A4-expressing cells, and MDP transport inhibition is measured.
|
| Cell Assay |
Cellular activity of AJ2-30 is evaluated in human plasmacytoid dendritic cells (pDCs) and primary human macrophages. Cells are treated with the compound, and IFN-α production or NOD signaling is measured.
|
| Animal Protocol |
In vivo efficacy of AJ2-30 is evaluated using PBMCs from lupus patients. Cytokine production is measured to assess the compound's immunosuppressive effects.
|
| ADME/Pharmacokinetics |
AJ2-30 has a molecular formula of C23H22N4 and a molecular weight of 354.45. Its SMILES code is CCN1C2=C(C=CC=C2)C3=CC(CNC4=NC5=C(N4C)C=CC=C5)=CC=C31. The compound is stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for AJ2-30 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
AJ2-30 is a specific SLC15A4 inhibitor that suppresses IFN-α production and inhibits MDP transport. It blocks endogenous NOD signaling in human and mouse macrophages. It can be used for inflammation research and is a valuable tool for studying autoimmune diseases such as lupus.
|
| Molecular Formula |
C23H22N4
|
|---|---|
| Molecular Weight |
354.447584629059
|
| Exact Mass |
354.18
|
| Elemental Analysis |
C, 77.94; H, 6.26; N, 15.81
|
| CAS # |
2700322-79-6
|
| PubChem CID |
163902400
|
| Appearance |
White to off-white solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
511
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN1C2=C(C=C(C=C2)CNC3=NC4=CC=CC=C4N3C)C5=CC=CC=C51
|
| InChi Key |
QKZNLVHPKAXDOL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H22N4/c1-3-27-20-10-6-4-8-17(20)18-14-16(12-13-21(18)27)15-24-23-25-19-9-5-7-11-22(19)26(23)2/h4-14H,3,15H2,1-2H3,(H,24,25)
|
| Chemical Name |
N-((9-ethyl-9H-carbazol-3-yl)methyl)-1-methyl-1H-benzo[d]imidazol-2-amine
|
| Synonyms |
AJ2-30; AJ230; AJ2 30
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~141.1 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (14.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (14.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8213 mL | 14.1064 mL | 28.2127 mL | |
| 5 mM | 0.5643 mL | 2.8213 mL | 5.6425 mL | |
| 10 mM | 0.2821 mL | 1.4106 mL | 2.8213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
